Erythropoietin and analogs

Handbook of Experimental Pharmacology

Volumn 195, Issue , 2010, Pages 251-294

  Reichel, Christian ^a   Gmeiner, Günter ^b  

^a ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^b NONE

Author keywords

Doping control; Erythropoietin; Isoelectric focusing; Protein mass spectrometry; RHuEPO

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; DRUG DERIVATIVE; RECOMBINANT PROTEIN;

ANALYTIC METHOD; ATHLETIC PERFORMANCE; CASE REPORT; CHROMATOGRAPHY; DOPING; ELECTROPHORESIS; ENDURANCE SPORT; ERYTHROPOIESIS; HUMAN; ISOELECTRIC FOCUSING; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TISSUE OXYGENATION; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECT; ERYTHROCYTE; LIQUID CHROMATOGRAPHY; METABOLISM;

ATHLETIC PERFORMANCE; CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ERYTHROCYTES; ERYTHROPOIETIN; HUMANS; MASS SPECTROMETRY; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS;

EID: 77449130942     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79088-4_12     Document Type: Review

References (175)

1. Abellan R et al (2007) Intermittent hypoxia exposure in a hypobaric chamber and erythropoietin abuse interpretation. J Sports Sci 25(11):1241-1250
2. Aktories K et al (2005) Allgemeine und spezielle Pharmakologie. Urban & Fischer, München
3. Ashenden MJ et al (2003) Effect of altitude on second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 88(9):1053-1062
4. Ashenden MJ et al (2004) Effect of pre-competition and altitude training on blood models used to detect erythropoietin abuse by athletes. Haematologica 89(8):1019-1020
5. Ashenden MJ et al (2006) The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica 91(8):1143-1144
6. Audran M et al (1999) Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 31(5):639-645
7. Bajla I et al (2001) Quantitative analysis of images in erythropoietin doping control. Med Biol Eng Comput 43(3):403-409
8. Bajla I et al (2005) GASepo - a software solution for quantitative analysis of digital images in Epo doping control. Comput Methods Programs Biomed 80(3):246-270
9. Balaguer E, Neusüss C (2006a) Glycoprotein characterization combining intact protein and glycan analysis by capillary electrophoresis- electrospray ionization-mass spectrometry. Anal Chem 78(15):5384-5393
10. Balaguer E, Neusüss C (2006b) Intact glycoform characterization of erythropoietin-alfa and erythropoietin-beta by CZE-ESI-TOF-MS. Chromatographia 64:351-357
11. Balaguer E et al (2006) Glycoform characterization of erythropoietin combining glycan and intact protein analysis by capillary electrophoresis- electrospray - time-of-flight mass spectrometry. Electrophoresis 27(13):2638-2650
12. Balsom PD et al (1994) Enhanced oxygen availability during high intensity intermittent exercise decreases anaerobic metabolite concentration in blood. Acta Physiol Scand 150:455-456
13. Barbone FP et al (1997) Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships. J Biol Chem 272:4985-4992
14. Barroso O et al (2008) Hormone abuse in sports: the antidoping perspective. Asian J Androl 10(3):391-402
15. Bartlett C et al (2006) Detection of the administration of human erythropoietin (HuEPO) to canines. J Anal Toxicol 30(9):663-669
16. Belalcazar V et al (2006) Assessing the instability of the isoelectric focusing patterns of erythro-poietin in urine. Electrophoresis 27(22):4387-4395
17. Berglund B (2002) Blood doping-a short background. In: Bowers L, Shymanski E (eds) Oxygen transport enhancing agents and methods, 1st edn. United States Anti-Doping Agency, Colorado Springs
18. Berglund B, Wide L (2002) Erythropoietin concentrations and isoforms in urine of anonymous Olympic athletes during the Nagano Olympic Games. Scand J Med Sci Sports 12(6):354-357
19. Berglund B et al (2003) Effect of short-term and intermittent normobaric hypoxia on endogenous erythropoietin isoforms. Scand J Med Sci Sports 13(2):124-127
20. Beullens M et al (2006) False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 107(12):4711-4713
21. Birkeland KI et al (2000) Effect of rhEPO administration on serum levels of STFR and cycling performance. Med Sci Sports Exerc 32(7):1238-1243
22. Bonsdorff E, Jalavisto E (1948) A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 16:150-170
23. Breidbach A et al (2003) Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin Chem 49(6):901-907
24. Bressolle F et al (1997) Population pharmacodynamics for monitoring epoetin in athletes. Clin Drug Invest 14:233-242
25. Bunn HF (2007) New agents that stimulate erythropoiesis. Blood 109(3):868-873
26. Caldini A et al (2001) Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics 3(6):937-941
27. Catlin DH et al (2003) Abuse of recombinant erythropoietins by athletes. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
28. Cazzola M (2000) A global strategy for prevention and detection of blood doping with erythro-poietin and related drugs. Haematologica 85(6):561-563
29. Cheetham JC et al (1998) NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5:861-866
30. Choi D et al (1996) Erythropoietin: physico- and biochemical analysis. J Chromatogr B Biomed Appl 687(1):189-199
31. Chuck AS et al (2003) Commercial production of recombinant erythropoietins. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
32. Cushner FD (2003) Use of erythropoietins in surgical settings. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
33. Dame C (2003) Molecular biology of the erythropoietin receptor in hematopoietic and non-hematopoietic tissues. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
34. Davis JM et al (1987) Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26:2633-2638
35. De Frutos M et al (2003) Differences in capillary electrophoresis profiles of urinary and recombinant erythropoietin. Electrophoresis 24(4):678-680
36. Deicher R, Hörl WH (2004) Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 64(5):499-509
37. Delanghe JR et al (2008) Testing for recombinant erythropoietin. Am J Hematol 83(3):237-241
38. DeLano WL (2007) The PyMOL Molecular Graphics System. DeLano Scientific LLC, Palo Alto, CA, USA. http://www.pymol.org
39. Desharnais P and Ayotte C (2007) Towards the screening of urinary Epo by SDS-PAGE analysis. In: Schänzer et al (ed) Recent advances in doping analysis (15), Sportverlag Strauss, Cologne
40. Donati A (2005) World trafficking of doping substanzes. http://www.wada-ama.org/rtecontent/ document/Donati-Report-Trafficking-2007-03- 06.pdf. Cited 16 August 2008
41. Dou P, Liu Z, He J, Xu JJ, Chen HY (2008) Rapid and high-resolution glycoform profiling of recombinant human erythropoietin by capillary isoelectric focusing with whole column imaging detection. J Chromatogr A 1190(1-2):372-376
42. Eagleton HJ, Littlewood TJ (2003) Update on the clinical use and misuse of erythropoietin. Curr Hematol Rep 2(2):109-115
43. Ebert BL, Bunn HF (1999) Regulation of the erythropoietin gene. Blood 74:1864-1877
44. Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16(3):3-13
45. Egrie JC et al (1993) The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 10:263
46. Eichner ER (2007) Blood doping: infusions, erythropoietin and artificial blood. Sports Med 37(4-5):389-391
47. Ekblom BT (2000) Blood boosting and sport. Baillieres Best Pract Res Clin Endocrinol Metab 14(1):89-98
48. Ekblom B, Berglund B (1991) Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports 1:88-93
49. Ekblom B et al (1972) Response to exercise after blood loss and reinfusion. J Appl Physiol 40:175-180
50. Elliott SG (2003) New molecules and formulations of recombinant human erythropoietin. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
51. Elliott SG et al (2004) Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol 32(12):1146-1155
52. European Medicines Agency (2004) NeoRecormon. Scientific Discussion. EMEA:1-14
53. European Medicines Agency (2007) Mircera. Scientific Discussion. EMEA:1-50
54. Fisher LM (1991) Stamina-building drug linked to athletes' deaths. NY Times 19:22
55. Foote MA (2003) Studies of erythropoiesis and the discovery and cloning of recombinant human erythropoietin. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
56. Franke WW, Heid H (2006) Pitfalls, errors and risks of false-positive results in urinary EPO drug tests. Clin Chim Acta 373(1-2):189-190
57. Gaudard A et al (2003) Drugs for increasing oxygen and their potential use in doping: a review. Sports Med 33(3):187-212
58. Giménez E et al (2007) Towards a reliable molecular mass determination of intact glycoproteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 21(16):2555-2563
59. Gore C et al (2003) Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 88(3):333-344
60. Groleau PE et al (2008) Low LC-MS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization. J Mass Spectrom 43(7):924-935
61. Guan F et al (2007) LC-MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin alpha in equine plasma. Anal Chem 79(12):4627-4635
62. Guan F et al (2008) Differentiation and identification of recombinant human erythropoietin and darbepoetin alfa in equine plasma by LC-MS/MS for doping control. Anal Chem 80(10): 3811-3817
63. Heatherington AC (2003) Clinical pharmacokintetic properties of rHuEPO: a review. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
64. Hokke CH et al (1995) Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units. Eur J Biochem 228 (3):981-1008
65. Imai N et al (1990) Physicochemical and biological comparison of recombinant human erythro-poietin with human urinary erythropoietin. J Biochem 107(3):352-359
66. Israels GL, Israels ED (2003) Erythropoiesis: an overview. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
67. Itoh S et al (2002) Simultaneous microanalysis of N-linked oligosaccharides in a glycoprotein using microbore graphitized carbon column liquid chromatography-mass spectrometry. J Chromatogr A 968(1-2):89-100
68. Jelkmann W (2003) Biochemistry and assay of erythropoietin. In: Jelkmann W (ed) Erythropoietin: Molecular biology and clinical use, 1st edn. F.P. Graham Publishing Co., Johnson City
69. Jelkmann W (2007a) Control of erythropoietin gene expression and its use in medicine. Methods Enzymol 435:179-197
70. Jelkmann W (2007b) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78(3):183-205
71. Jelkmann W (2007c) Novel erythropoietic agents: a threat to sportsmanship. Medicina Sportiva 11 (2):32-42
72. Jelkmann W (2008) Developments in the therapeutic use of erythropoiesis stimulating agents. Br J Haematol 141(3):287-297
73. Kanazawa K et al (1999) Establishment of a method for mapping of N-linked oligosaccharides and its use to analyze industrially produced recombinant erythropoietin. Biol Pharm Bull 22 (4):339-346
74. Kanstrup IL, Ekblum B (1984) Blood volume and hemoglobin concentration as determinants of maximal aerobic power. Med Sci Sprots Exerc 16:256-262
75. Kawasaki N et al (1999) Analysis of carbohydrate heterogeneity in a glycoprotein using liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry. Anal Biochem 269(2):297-303
76. Kawasaki N et al (2000) Application of liquid chromatography/mass spectrometry and liquid chromatography with tandem mass spectrometry to the analysis of the site-specific carbohydrate heterogeneity in erythropoietin. Anal Biochem 285(1):82-91
77. Kawasaki N et al (2001) Structural analysis of sulfated N-linked oligosaccharides in erythropoietin. Glycobiology 11(12):1043-1049
78. Kawasaki N et al (2002) Usefulness of sugar mapping by liquid chromatography/mass spectrometry in comparability assessments of glycoprotein products. Biologicals 30(2):113-123
79. Kazlauskas R et al (2002) Strategies for rHuEPO detection in sport. Clin J Sport Med 12(4):229-235
80. Kearns CF et al (2000) Cross reactivity between human erythropoietin antibody and horse erythropoietin. Electrophoresis 21(8):1454-1457
81. Khan A, Baker MS (2007) Non-specific binding of monoclonal human erythropoietin antibody AE7A5 to Escherichia coli and Saccharomyces cerevisiae proteins. Clin Chim Acta 379(1-2): 173-175
82. Khan A et al (2005) New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 358(1-2):119-130
83. Kohler M et al (2008) Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int J Sports Med 29(1):1-6
84. Kung CK, Goldwasser E (1997) A probable conformational difference between recombinant and urinary erythropoietins. Proteins 28(1):94-98
85. La Merie (2008) Erythropoietins: the shift from biosimilars to "more for less" ESAs. http://www. lamerie.com/press-room/erythropoietins- biosimilars-esas.html. Cited 17 August 2008
86. Lage JM et al (2002) Cyclist's doping associated with cerebral sinus thrombosis. Neurology 58 (4):665
87. Lamon S et al (2007a) Detection window of Darbepoetin-alpha following one single subcutaneous injection. Clin Chim Acta 379(1-2):145-149
88. Lamon S et al (2007b) Possible origins of undetectable EPO in urine samples. Clin Chim Acta 385 (1-2):61-66
89. Lasne F (2001) Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 253(1-2):125-131
90. Lasne F (2003) Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 276(1-2):223-226
91. Lasne F (2006) No doubt about the validity of the urine test for detection of recombinant human erythropoietin. Blood 108(5):1778-1779
92. Lasne F, de Ceaurriz J (2000) No doubt about the validity of the urine test for detection of recombinant human erythropoietin. Recombinant erythropietin in urine. Nature 405:635
93. Lasne F et al (2002) Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311(2):119-126
94. Lasne F et al (2005) Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. J Anal Toxicol 29(8):835-837
95. Lasne F et al (2007a) Isoelectric profiles of human erythropoietin are different in serum and urine. Int J Biol Macromol 41:354-357
96. Lasne F et al (2007b) Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis. Electrophoresis 28(12): 1875-1881
97. Lin FK et al (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580-7582
98. Linsley KB et al (1994) Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans. Anal Biochem 219(2):207-217
99. Llop E et al (2007) Evaluation of protein N-glycosylation in 2-DE: Erythropoietin as a study case. Proteomics 7(23):4278-4291
100. Lönnberg M, Carlsson J (2000) Membrane assisted isoform immunoassay. A rapid method for the separation and determination of protein isoforms in an integrated immunoassay. J Immunol Methods 246(1-2):25-36
101. Lönnberg M, Carlsson J (2001a) Quantitative detection in the attomole range for immunochromatographic tests by means of a flatbed scanner. Anal Biochem 293(2):224-231
102. Lönnberg M, Carlsson J (2001b) Chromatographic performance of a thin microporous bed of nitrocellulose. J Chromatogr B Biomed Sci Appl 763(1-2):107-120
103. Lönnberg M, Carlsson J (2006) Lab-on-a-chip technology for determination of protein isoform profiles. J Chromatogr A 1127(1-2):175-182
104. Macdougall IC (2001) An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16(3):14-21
105. Macdougall IC (2003) Use of recombinant erythropoietins in the setting of renal disease. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
106. Masuda S et al (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269(30):19488-19493
107. Miyake T et al (1977) Purification of human erythropoietin. J Biol Chem 252:5558-5564
108. Mo W et al (1998) Structural analysis of oligosaccharides derivatized with 4-aminobenzoic acid 2-(diethylamino) ethyl ester by matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem 70(21):4520-4526
109. Molineux G (2003) Biology of erythropoietin. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
110. Morkeberg J et al (2007) Detection of darbepoetin alfa misuse in urine and blood: a preliminary investigation. Med Sci Sports Exerc 39(10):1742-1747
111. Narhi LO et al (1991) The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266(34):23022-23026
112. Neusüss C et al (2005) Glycoform characterization of intact erythropoietin by capillary electro-phoresis-electrospray-time of flight-mass spectrometry. Electrophoresis 6(7-8):1442-1450
113. Nimtz M et al (1993) Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 213(1):39-56
114. Nimtz M et al (1995) Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett 365(2-3):203-208
115. Ohta M et al (2001) Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr A 910 (1):1-11
116. Ohta M et al (2002) Usefulness of glycopeptide mapping by liquid chromatography/mass spectrometry in comparability assessment of glycoprotein products. Biologicals 30(3):235-244
117. Organization WH (2006) International nonproprietary names (INN) for biological and biotechnological substances. INN Working Document 05(179):1-29
118. Osslund T, Syed R (2003) Structural basis for the signal transduction of erythropoietin. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser Verlag, Basel
119. Overbay DK, Manley HJ (2002) Darbepoetin-alpha: a review of the literature. Pharmacotherapy 22(7):889-897
120. Parisotto R et al (2000a) A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 85(6):564-572
121. Parisotto R et al (2000b) Reticulocyte parameters as potential discriminators of recombinant human erythropoietin abuse in elite athletes. Int J Sports Med 21(7):471-479
122. Parisotto R et al (2001) Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 86(2):128-137
123. Pascual JA et al (2004) Recombinant erythropoietin and analogues: a challenge for doping control. Ther Drug Monit 26(2):175-179
124. Philo JS et al (1996) Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 35:1681-1691
125. Rabin OP et al (2006) New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 373(1-2):186-187
126. Rahbek-Nielsen H et al (1997) Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 32(9):948-958
127. Recny MA et al (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262(35):17156-17163
128. Reichel C (2007) Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 anti-human EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. In: Schänzer et al (ed) Recent advances in doping analysis (15). Sportverlag Strauss, Cologne
129. Reichel C (2008) SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Manfred Donike Workshop (oral presentation) - 26th Cologne Workshop in Doping Analysis Cologne, Germany. February 24-29, 2008
130. Reichel C et al (2006) Improvement in the background correction of EPO IEF images. In: Schänzer et al (ed) Recent advances in doping analysis (14). Sportverlag Strauss, Cologne
131. Reichel C et al (2009) SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Anal 1:43-50
132. Rice KG et al (1992) Quantitative mapping of the N-linked sialyloligosaccharides of recombinant erythropoietin: combination of direct high-performance anion-exchange chromatography and 2-aminopyridine derivatization. Anal Biochem 206(2):278-287
133. Robinson N et al (2006) Erythropoietin and blood doping. Br J Sports Med 40(Suppl 1):i30-i34
134. Robinson N et al (2007) Bayesian detection of abnormal hematological values to introduce a no-start rule for heterogeneous populations of athletes. Haematologica 92(8):1143-1144
135. Rush RS et al (1995) Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 67(8):1442-1452
136. Russel G et al (2002) Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol 86:442-449
137. Sanz-Nebot V et al (2003) Separation of recombinant human erythropoietin glycoforms by capillary electrophoresis using volatile electrolytes. Assessment of mass spectrometry for the characterization of erythropoietin glycoforms. Anal Chem 75(19):5220-5229
138. Sasaki H et al (1987) Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262(25):12059-12076
139. Sasaki H et al (1988) Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 27(23):8618-8626
140. Schellekens H (2004) Biosimilar epoetins: how similar are they? EHLP Journal 3:43-47
141. Schellekens H (2005) Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant 4:31-36
142. Schlags W et al (2002) Two-dimensional electrophoresis of recombinant human erythropoietin: a future method for the European Pharmacopoeia? Proteomics 2(6):679-682
143. Segura J et al (2007) Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal Bioanal Chem 388(7):1521-1529
144. Sharpe K et al (2002) Development of reference ranges in elite athletes for markers of altered erythropoiesis. Haematologica 87(12):1248-1257
145. Sharpe K et al (2006) A third generation approach to detect erythropoietin abuse in athletes. Haematologica 91(3):356-363
146. Sherwood JB et al (1988) The heterogeneity of circulating human serum erythropoietin. Endocrinology 122:1472-1477
147. Siegmund-Schultze N (2007) Doping: Jede Diagnose kann geschönt werden. Dtsch Arztebl. http://www.aerzteblatt.de/v4/archiv/artikel.asp?src= heft&id=57223. Cited 16 September 2008
148. Singh AK, Gupta S (2007) Analysis of recombinant human erythropoietin and darbepoietin in spiked plasma. Proteomics 1(7):625-716
149. Skibeli V et al (2001) Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98(13):3626-3634
150. Skibeli V et al (2003) Immunomagnetic extraction as a tool for the analysis of human serum erythropoietin. DYNALogue 1:13-15
151. Sottani C et al (1997) Matrix performance in matrix-assisted laser desorption/ionization for molecular weight determination in sialyl and non-sialyl oligosaccharide proteins. Rapid Commun Mass Spectrom 11(8):907-913
152. Stanley SM, Poljak A (2003) Matrix-assisted laser-desorption time-of flight ionisation and high-performance liquid chromatography-electrospray ionisation mass spectral analyses of two glycosylated recombinant epoetins. J Chromatogr B Analyt Technol Biomed Life Sci 785 (2):205-218
153. Stead RB et al (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108(6):1830-1834
154. Stolc S, Bajla I (2006) Improvement of band segmentation in Epo images via column shift transformation with cost functions. Med Biol Eng Comput 44(4):257-274
155. Storring PL et al (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100(1):79-89
156. Stübiger G et al (2005a) Characterization of N- and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry. J Sep Sci 28(14):1764-1778
157. Stübiger G et al (2005b) Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 19(5):728-742
158. Syed RS et al (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511-516
159. Sytkowski AJ (2004) Erythropoietin. Blood, brain and beyond. Wiley-VCH, Weinheim, p 63, 192
160. Sytkowski AJ, Fisher JW (1985) Isolation and characterization of an anti-peptide monoclonal antibody to human erythropoietin. J Biol Chem 260(27):14727-14731
161. Takegawa Y et al (2008) Profiling of N- and O-glycopeptides of erythropoietin by capillary zwitterionic type of hydrophilic interaction chromatography/electrospray ionization mass spectrometry. J Sep Sci 31(9):1585-1593
162. Tam RC et al (1991) Comparisons of human, rat and mouse erythropoietins by isoelectric focusing: differences between serum and urinary erythropoietins. Br J Haematol 79(3):504-511
163. Thevis M et al (2007) Proteases in doping control analysis. Int J Sports Med 28(7):545-549
164. Tsuda E et al (1988) Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry 27(15):5646-5654
165. Watson E, Yao F (1993) Capillary electrophoretic separation of human recombinant erythropoietin (r-HuEPO) glycoforms. Anal Biochem 210(2):389-393
166. Westermeier R (2004) Electrophoresis in practice: a guide to methods and applications of DNA and protein separations. Wiley-VCH, Weinheim
167. Wide L, Bengtsson C (1990) Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 76(1):121-127
168. Wide L et al (1995) Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 27(11):1569-1576
169. World Anti-Doping Agency (2007) Harmonization of the method for the identification of epoetin alfa and beta (rEPO) and darbepoetin alfa (NESP) by IEF-double blotting and chemiluminescent detection. http://www.wada-ama.org/ rtecontent/document/td2007epo-en.pdf. Cited 16 August 2008
170. World Anti-Doping Agency (2008) The World Anti-Doping Code, 2008 Prohibited List http://www.wada-ama.org/rtecontent/document/2008-List-En.pdf. Cited 16 August 2008
171. Yu B et al (2005) Ionene-dynamically coated capillary for analysis of urinary and recombinant human erythropoietin by capillary electrophoresis and online electrospray ionization mass spectrometry. J Sep Sci 28(17):2390-2400
172. Yuan J et al (2005) Isotope tag method for quantitative analysis of carbohydrates by liquid chromatography-mass spectrometry. J Chromatogr A 1067(1-2):145-152
173. Yuen CT et al (2003) Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Br J Haematol 121(3):511-526
174. Zhou GH et al (1998) Application of capillary electrophoresis, liquid chromatography, electrospray-mass spectrometry and matrix-assisted laser desorption/ionization - time of flight - mass spectrometry to the characterization of recombinant human erythropoietin. Electrophoresis 19(13):2348-2355
175. Zotter H et al (2004) Abnormally high serum ferritin levels among professional road cyclists. Br J Sports Med 38(6):704-708